Introduction Intraoperative and postoperative blood loss is a major concern and challenge for surgeons in total joint arthroplasty (TJA). Patients with large blood loss can develop postoperative anemia and associated complications. Novel hemostatic agents, such as oxidized regenerated cellulose (ORC) have grown in popularity as intraoperative hemostatic adjuncts. The aim of this systematic review and meta-analysis is to evaluate the efficacy of ORC for intraoperative and postoperative blood loss.
Methods A search was conducted across MEDLINE/Pubmed, Cochrane, Google Scholar, Web of Science, and Embase databases. Titles and abstracts were screened for eligibility for inclusion criteria. Full texts were screened and included if they met eligibility criteria. Demographics and results of the studies were extracted from the articles that met inclusion criteria. Meta-analysis was conducted to evaluate outcomes.
Results Eleven studies met inclusion criteria. There were four Level 1 evidence studies, one Level 2 evidence study, five Level 3 evidence studies, and one Level 4 evidence study. One case report study did report a hypersensitivity reaction, however, the remaining studies showed no additional complications from the use of ORC. Five studies reported equivalent rates of blood transfusion, with one study finding that ORC led to lower rates of blood transfusions. Nine studies were included for meta-analysis. Total blood loss (Cohen’s d: -0.42, CI: -0.66- -0.19, p
Conclusion ORC may help to reduce total blood loss and intraoperative blood loss in TJA, however, it does not appear to have sustained effects over the following week, nor does it appear to lower transfusion rates with the current available evidence. ORC has been shown to be safe, with CRP levels remaining constant postoperatively, and only one case report showing a self-limited hypersensitivity reaction (local rash). ORC may be a useful adjunct to help reduce blood loss for TJA, however, it is not currently clear if its usage leads to significant improvements in clinical outcomes.

81dbb1c7-778b-4944-9eda-7837b4d82cb5
0a72d7ad-8b7a-45d1-80d5-02b00d6e6570
6fc5438f-0118-48ff-856f-5fc737346780
c4643335-bf75-4cc0-8c93-5c0b8f4728ba
a7cd047e-e3c3-4134-9818-c2293ae27e69
59a7cac1-3f15-406a-9a23-96d360742a5b